KFDA Delays Decision on Hanmi’s Anti-Obesity Drug with Novel Salt Formulation

Published: 2005-03-14 07:00:00

Updated: 2005-03-14 07:00:00

The delayed decision by the Korea Food and Drug Administration (KFDA) on an approval of Hanmi Pharmaceutical’s anti-obesity drug Slimer is triggering debates on the current regulatory process that governs the approval of new chemical drugs with novel salt formulation during the re-examination per...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK